ORGANIZATION

7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey

November 9, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s drug pricing overhaul in April has prompted 50% of EFPIA Japan member companies affected by policy changes to revise their R&D strategy in the country by September, according to a survey conducted by the trade group. EFPIA Japan, or…

To read the full story

9 EFPIA Companies Reviewed Headcount Planning after Drug Pricing Overhaul: Survey
December 5, 2018

ORGANIZATION

JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
Five Groups Urge Action to Secure Medical Supplies amid Iran War
April 2, 2026
UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
April 2, 2026
JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing

By Sakura Kono

Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…